vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and New Fortress Energy Inc. (NFE). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $326.2M, roughly 1.5× New Fortress Energy Inc.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -259.7%, a 249.5% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -7.0%). CLOVER HEALTH INVESTMENTS, CORP. produced more free cash flow last quarter ($-69.0M vs $-134.8M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -26.8%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

New Fortress Energy Inc. is a global energy infrastructure firm developing, owning and operating LNG import/export terminals, natural gas supply networks and low-carbon projects. It serves utility, industrial and public sector clients across the Americas and Caribbean, delivering affordable, lower-emission energy resources.

CLOV vs NFE — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.5× larger
CLOV
$487.7M
$326.2M
NFE
Growing faster (revenue YoY)
CLOV
CLOV
+51.7% gap
CLOV
44.7%
-7.0%
NFE
Higher net margin
CLOV
CLOV
249.5% more per $
CLOV
-10.1%
-259.7%
NFE
More free cash flow
CLOV
CLOV
$65.8M more FCF
CLOV
$-69.0M
$-134.8M
NFE
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-26.8%
NFE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
NFE
NFE
Revenue
$487.7M
$326.2M
Net Profit
$-49.3M
$-847.1M
Gross Margin
35.5%
Operating Margin
-10.1%
-193.0%
Net Margin
-10.1%
-259.7%
Revenue YoY
44.7%
-7.0%
Net Profit YoY
-123.2%
-277.4%
EPS (diluted)
$-3.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
NFE
NFE
Q4 25
$487.7M
$326.2M
Q3 25
$496.6M
$240.3M
Q2 25
$477.6M
$228.1M
Q1 25
$462.3M
$384.9M
Q4 24
$337.0M
$350.7M
Q3 24
$331.0M
$446.0M
Q2 24
$356.3M
$291.2M
Q1 24
$346.9M
$609.5M
Net Profit
CLOV
CLOV
NFE
NFE
Q4 25
$-49.3M
$-847.1M
Q3 25
$-24.4M
$-263.0M
Q2 25
$-10.6M
$-546.5M
Q1 25
$-1.3M
$-175.4M
Q4 24
$-22.1M
$-224.4M
Q3 24
$-9.2M
$9.3M
Q2 24
$7.4M
$-88.9M
Q1 24
$-19.2M
$54.1M
Gross Margin
CLOV
CLOV
NFE
NFE
Q4 25
35.5%
Q3 25
18.1%
Q2 25
8.4%
Q1 25
21.4%
Q4 24
17.6%
Q3 24
24.5%
27.1%
Q2 24
30.3%
23.8%
Q1 24
23.6%
62.4%
Operating Margin
CLOV
CLOV
NFE
NFE
Q4 25
-10.1%
-193.0%
Q3 25
-4.9%
-37.4%
Q2 25
-2.2%
-170.3%
Q1 25
-0.3%
-3.3%
Q4 24
-6.4%
65.0%
Q3 24
-2.7%
17.8%
Q2 24
2.0%
12.3%
Q1 24
-6.5%
30.4%
Net Margin
CLOV
CLOV
NFE
NFE
Q4 25
-10.1%
-259.7%
Q3 25
-4.9%
-109.4%
Q2 25
-2.2%
-239.6%
Q1 25
-0.3%
-45.6%
Q4 24
-6.6%
-64.0%
Q3 24
-2.8%
2.1%
Q2 24
2.1%
-30.5%
Q1 24
-5.5%
8.9%
EPS (diluted)
CLOV
CLOV
NFE
NFE
Q4 25
$-3.03
Q3 25
$-0.96
Q2 25
$-1.99
Q1 25
$-0.65
Q4 24
$-1.10
Q3 24
$0.03
Q2 24
$-0.42
Q1 24
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
NFE
NFE
Cash + ST InvestmentsLiquidity on hand
$78.3M
$226.5M
Total DebtLower is stronger
$8.2B
Stockholders' EquityBook value
$308.7M
$182.6M
Total Assets
$541.0M
$10.6B
Debt / EquityLower = less leverage
44.78×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
NFE
NFE
Q4 25
$78.3M
$226.5M
Q3 25
$145.2M
Q2 25
$551.1M
Q1 25
$447.9M
Q4 24
$194.5M
$492.9M
Q3 24
$288.0M
$90.8M
Q2 24
$254.8M
$133.0M
Q1 24
$208.3M
$143.5M
Total Debt
CLOV
CLOV
NFE
NFE
Q4 25
$8.2B
Q3 25
Q2 25
Q1 25
Q4 24
$8.9B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CLOV
CLOV
NFE
NFE
Q4 25
$308.7M
$182.6M
Q3 25
$340.9M
$1.1B
Q2 25
$344.2M
$1.3B
Q1 25
$336.1M
$1.8B
Q4 24
$341.1M
$1.9B
Q3 24
$342.2M
$1.6B
Q2 24
$324.9M
$1.6B
Q1 24
$292.5M
$1.7B
Total Assets
CLOV
CLOV
NFE
NFE
Q4 25
$541.0M
$10.6B
Q3 25
$559.7M
$12.0B
Q2 25
$575.0M
$12.0B
Q1 25
$583.7M
$13.1B
Q4 24
$580.7M
$12.9B
Q3 24
$653.0M
$12.0B
Q2 24
$674.2M
$11.4B
Q1 24
$671.8M
$10.9B
Debt / Equity
CLOV
CLOV
NFE
NFE
Q4 25
44.78×
Q3 25
Q2 25
Q1 25
Q4 24
4.74×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
NFE
NFE
Operating Cash FlowLast quarter
$-66.9M
$-76.2M
Free Cash FlowOCF − Capex
$-69.0M
$-134.8M
FCF MarginFCF / Revenue
-14.1%
-41.3%
Capex IntensityCapex / Revenue
0.4%
18.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$-1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
NFE
NFE
Q4 25
$-66.9M
$-76.2M
Q3 25
$12.1M
$-171.0M
Q2 25
$5.4M
$-329.0M
Q1 25
$-16.3M
$-7.2M
Q4 24
$34.8M
$445.3M
Q3 24
$50.0M
$-20.0M
Q2 24
$44.8M
$113.9M
Q1 24
$25.9M
$63.0M
Free Cash Flow
CLOV
CLOV
NFE
NFE
Q4 25
$-69.0M
$-134.8M
Q3 25
$11.4M
$-231.6M
Q2 25
$4.8M
$-726.7M
Q1 25
$-16.5M
$-262.3M
Q4 24
$33.3M
$-210.3M
Q3 24
$49.6M
$-367.0M
Q2 24
$44.4M
$-493.2M
Q1 24
$25.5M
$-457.9M
FCF Margin
CLOV
CLOV
NFE
NFE
Q4 25
-14.1%
-41.3%
Q3 25
2.3%
-96.4%
Q2 25
1.0%
-318.6%
Q1 25
-3.6%
-68.2%
Q4 24
9.9%
-60.0%
Q3 24
15.0%
-82.3%
Q2 24
12.5%
-169.3%
Q1 24
7.3%
-75.1%
Capex Intensity
CLOV
CLOV
NFE
NFE
Q4 25
0.4%
18.0%
Q3 25
0.1%
25.2%
Q2 25
0.1%
174.4%
Q1 25
0.0%
66.3%
Q4 24
0.5%
187.0%
Q3 24
0.1%
77.8%
Q2 24
0.1%
208.4%
Q1 24
0.1%
85.5%
Cash Conversion
CLOV
CLOV
NFE
NFE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-2.15×
Q2 24
6.04×
Q1 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons